Revolution Medicines Inc (RVMD)vsSouthern Company (The) Series 2 (SOJE)
RVMD
Revolution Medicines Inc
$140.55
-2.96%
HEALTHCARE · Cap: $29.88B
SOJE
Southern Company (The) Series 2
$17.22
-1.03%
NONE · Cap: $65.72B
Smart Verdict
WallStSmart Research — data-driven comparison
SOJE leads profitability with a 0.0% profit margin vs 0.0%. SOJE earns a higher WallStSmart Score of 25/100 (F).
RVMD
Avoid24
out of 100
Grade: F
SOJE
Avoid25
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
Trading at 17.0x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : RVMD
The strongest argument for RVMD centers on Altman Z-Score.
Bull Case : SOJE
The strongest argument for SOJE centers on Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Bear Case : SOJE
The primary concerns for SOJE are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
SOJE is growing revenue faster at 0.0% — sustainability is the question.
RVMD generates stronger free cash flow (-276M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SOJE scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Southern Company (The) Series 2
NONE · NONE · USA
Southern Company Series 2 is a prominent entity in the utility sector, specializing in the provision of reliable and sustainable energy solutions primarily across the Southeastern United States. As a subsidiary of the larger Southern Company, it benefits from a solid financial footing and a diversified energy mix that includes natural gas, nuclear, and renewable resources. The company's forward-thinking approach to innovation and dedication to environmental stewardship positions it strategically for the ongoing energy transition, thus appealing to institutional investors. Additionally, its strong regulatory framework and commitment to enhancing energy infrastructure further equip Southern Company Series 2 to navigate the evolving challenges of the energy market effectively.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?